


Activity Report 2016

CIC 
bioGUNE

Biozientzietako Ikerkuntza Kooperatiboko Zentroa
Centro de Investigación Cooperativa en Biociencias





Vision:

CIC bioGUNE (Centre for Cooperative Research in Biosciences) is a non-profit research organisation focused on performing research of excellence in Life Sciences. Founded in 2002 through an initiative of the Department of Industry of the Basque Government (currently Department of Economic Development and Infrastructures), it has become a pillar of the Basque Country's growing bioscience sector and a model for efficient cooperation between the different agents of the Basque Innovation System.

Mission:

CIC bioGUNE's mission is to perform basic research that excels at the international level, focused on strategic aims: to play a major role in the advancement of biomedical research and technological innovation and to support the development of the biotechnology and bioscience industry in the Basque Country.


Values:

CIC bioGUNE prioritises scientific opportunities with the strongest service potential and the highest capacity to improve the quality of life of society. CIC bioGUNE adheres to the following values:

- Our projects and activities will be conducted in the firm belief that scientific excellence may only be fostered in a free and tolerant environment.
- Our projects and activities will seek to promote the human and professional development of those involved in achieving our goals.
- Our resources and projects will be administered, directed and assessed in order to reaffirm the trust placed in us by the Basque Administration.



Total 2016 R&D Budget: **11.459** million €
N. R&D Projects: **57**



87% Public Funding
52,76% competitive + **47,24%** non-competitive

13% Private Funding


56% Basque Government Departments
6.399 K€

20% MINECO & MEDC (Spanish Government)
2.286 K€

13% R&D Contracts, Research Services & Others
1.498 K€

8% EU & International Projects
871 K€

3% Bizkaia County Council & Others
405 K€



Staff 2016



Staff 2016.12.31: **164**
 Average Age: **37.2** years
 Permanent staff: **52%**



55.5% Female
91

44.5% Male
73



164 Total CIC bioGUNE Personnel

83.5% Research
137


16.5% Administration and services
27

Research distribution by Professional Category

	n°	%	♀	♂
Researches	95	69.3	41	54
• Principal Investigators / Platform Managers	25	18.2	7	18
• Postdoctoral Researches / Research Assistant / Specialist	36	26.3	15	21
• PhD Student	34	24.8	19	15
Technicians	42	30.7	33	9

Research distribution by National Origin

- Spain 73
- Italy 6
- Portugal 2
- Austria 2
- United Kingdom 1
- Holland 1
- Albania 1
- Germany 1
- America 6
- Asia 2



76.8% Spanish
73 researchers

14.8% Rest of Europe
14 researchers

6.3% America
6 researchers

2.1% Asia
2 researchers

Scientific Output 2016



Publications: **106**
Citations: **2.446 (*)**
Impact Factor: **6.9**
Average HIRSCH Index: **52 (*)**

Lectures at Meetings: **54**
Lectures at Institutions: **36**
PhD Tesis: **9**


106 publications in 2016




86 First Quartile

31 First Decil


Impact Factor



Citations



(*) Web of Science





New Patent Applications: **11**
New Collaboration Agreements: **7**
New Research Contracts: **13**
Economic Activity: **1.107.328 €**

3 Licensed Patents
1 new US Patent: **US 9.437.765**
1 new EPO Patent: **EP 2.384.702 (B1)**

Customer Base: **57**

Basque Country: **34.3 %**
National: **19.3 %**
International: **46.4 %**

11 New Patent Applications




4 European Patent Application

3 PCT Patent Application

2 Spanish Patent Application

2 USPTO Patent Application





Metabolism and Cell Signaling in Disease

Personalized medicine
Prostate Cancer
Breast Cancer
Colorectal Cancer
Liver Diseases
Rare Diseases
Biomarkers for Diagnosis
Biomarkers for Prognosis
Drug Design and Discovery



Molecular Recognition and Host-Pathogen

Rare Diseases
Homeostasis
Viral Infections
Bacterial Infections
Prion Disease
Tick-Borne Disease
Immune Response
Drug Design and Discovery



Platform

NMR Spectroscopy
Macromolecular Crystallography
Electron Microscopy
Genome Analysis
Proteomics
Metabolomics
Animal Facility



New recruitments

Research lines:

1. Carbohydrate modifying enzymes

Glycosyltransferases, Glycoside hydrolases, Esterases, Auxiliary activities, CBMs...

2. Bacterial pathogenesis

Mycobacterium tuberculosis



Marcelo Guerin
Group Leader

Comes from Leloir Institute, Argentina

His interest in glycobiochemistry began as an undergraduate student, while working with glycosyl hydrolases in the Leloir Institute at Buenos Aires, Argentina (1991-1996). This research center was named in honor to Luis F. Leloir, who discovered the first sugar nucleotide and was awarded the Nobel Prize in Chemistry in 1970.

He then completed his doctoral studies in biochemistry and molecular biology studying mechanistic aspects of glycosyltransferases in the Leloir Institute (1997-2002). To further advance toward the understanding of the molecular mechanism that governs glycosyl transfer reactions, he moved to the Structural Biochemistry Unit at the Institut Pasteur in Paris, France, where he was first introduced to macromolecular crystallography (2003-2007). After this postdoctoral training, he continued his work on the mycobacterial cell envelope when he transferred as a postdoctoral fellow to the Mycobacteria Research Laboratories in the Department of Microbiology, at Colorado State University in the United States (2008-2009). In 2009, he was awarded an Ikerbasque Research Professor position as the Head of the Structural Glycobiochemistry Group (SGP).

He started his work at the Unit of Biophysics (CSIC-UPV), the Basque Country, Spain. More recently, he moved to the Structural Biology Unit, CIC bioGUNE as the Head of the Structural Glycobiochemistry Lab. He is particularly interested in investigating the structural and mechanistic properties of carbohydrate modifying enzymes. To this end, the group is using a multidisciplinary approach including protein biochemistry, protein biophysics and structural biology.



David Albesa-Jové
Senior Scientist


Comes from Imperial College London, United Kingdom

His interest in structural biology and bacterial pathogenicity began at Imperial College London, where he developed his research in the Centre for Molecular Bacteriology and Infection of the Medical Research Council, London, UK (2006-2011). This research center is an international reference point in molecular, cellular and structural aspects of bacterial pathogenesis.

Previous to this, he completed his doctoral studies in chemistry at the University of Birmingham, Birmingham, UK (2000-2004), followed by a first postdoctoral training in the Department of Chemistry at the University of Durham, Durham, UK (2004-2006).


To further advance towards the understanding of the molecular mechanism that underline bacterial pathogenesis, he moved to the Structural Glycobiochemistry Laboratory (2011 to present), where he focuses on the structural bases of glycolipid biosynthesis in bacteria.

In 2014, he was awarded an Ikerbasque Research Fellowship, a highly competitive program that provides a path towards an independent research career. To this end, he is using a multidisciplinary approach including protein biochemistry, protein biophysics and structural biology to study the involvement of the Type 6 Secretion System in bacterial competition and human pathogenicity.



Structural Mechanism for Cargo Recognition by the Retromer Complex
Lucas M, Gershlick DC, Vidaurrazaga A, Rojas AL, Bonifacino JS, Hierro A.

Cell. 2016 Dec 1;167(6):1623-1635.e14. doi: 10.1016/j.cell.2016.10.056



Fine Tuning of CD8 (+) T Cell Mitochondrial Metabolism by the Respiratory Chain Reporter MCJ Dictates Protection to Influenza Virus


Champagne DP, Hatle KM, Fortner KA, D'Alessandro A, Thornton TM, Yang R, Torralba D, Tomás-Cortázar J, Jun YW, Ahn KH, Hansen KC, Haynes L, Anguita J, Rincon M.



Catching elusive glycosyl cations in a condensed phase with HF/SbF₆ superacid

Martin A, Arda A, Désiré J, Martin-Mingot A, Probst N, Sinaÿ P, Jiménez-Barbero J, Thibaudeau S, Blériot Y

Nat Chem. 2016 Feb;8(2):186-91. doi: 10.1038/nchem.2399



The metabolic co-regulator PGC1 α suppresses prostate cancer metastasis

Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernández-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zúñiga-García P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martín-Martín N, David Sutherland J, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A, Tomás-Cortázar J, Jun YW, Ahn KH, Hansen KC, Haynes L, Anguita J, Rincon M.

Nat Cell Biol. 2016 Jun;18(6):645-56. doi: 10.1038/ncb3357



The democratization of cryo-EM

Stuart DI, Subramaniam S, Abrescia NG.


Mat Methods. 2016 Jul 28;13(8):607-8. doi: 10.1038/nmeth.3946



Neovascularization-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

Villa E, Critelli R, Lei B, Marzocchi G, Cammà C, Giannelli G, Pontisso P, Cabibbo G, Enea M, Colopi S, Caporali C, Pollicino T, Milosa F, Karampatou A, Todesca P, Bertolini E, Maccio L, Martínez-Chantar ML, Turolo E, Del Buono M, De Maria N, Ballestri S, Schepis F, Loria P, Enrico Gerunda G, Losi L, Cillo U.


Gut. 2016 May;65(5):861-9. doi: 10.1136/gutjnl-2014-308483



Cross-Species Interferon Signaling Boosts Microbicidal Activity within the Tick Vector

Smith AA, Navasa N, Yang X, Wilder CN, Buyuktanir O, Marques A, Anguita J, Pal U.

Cell Host Microbe. 2016 Jul 13;20(1):91-8. doi: 10.1016/j.chom.2016.06.001



Evolution of SUMO Function and Chain Formation in Insects

Ureña E, Pirone L, Chafino S, Pérez C, Sutherland JD, Lang V, Rodriguez MS, Lopitz-Otsoa F, Blanco FJ, Barrio R, Martín D.

Mol Biol Evol. 2016 Feb;33(2):568-84. doi: 10.1093/molbev/msv242.



Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cell through programmed death ligand 1

Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, Reche PA, López-Relaño J, Martínez-Naves E, Cañada FJ, Jiménez-Barbero J, Subiza J, Casanovas M, Fernández-Caldas E, Subiza JL, Palomares O.

J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11. doi: 10.1016/j.jaci.2016.02.029



Finding the Right Candidate for the Right Position: A Solid NMR-Assisted Combinatorial Method for Optimizing Nucleic Acids Binders.

Jiménez-Moreno E, Montalvillo-Jiménez L, Santana AG, Gómez AM, Jiménez-Osés G, Corzana F, Bastida A, Jiménez-Barbero J, Cañada FJ, Gómez-Pinto I, González C, Asensio JL.

J Am Chem Soc. 2016 May 25;138(20):6463-74. doi: 10.1021/jacs.6b00328



Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of L-asparaginase in childhood ALL cells.

Hermanova I, Arruabarrena-Aristorena A, Valis K, Nuskova H, Alberich-Jorda M, Fiser K, Fernandez-Ruiz S, Kavan D, Pecinova A, Niso-Santano M, Zaliova M, Novak P, Houstek J, Mracek T, Kroemer G, Carracedo A, Trka J, Starkova J.


Leukemia. 2016 Jan;30(1):209-1



Deregulated methionine adenosyltransferase α 1, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans (#)

Yang H, Liu T, Wang J, Li TW, Fan W, Peng H, Krishnan A, Gores GJ, Mato JM, Lu SC.

Hepatology. 2016 Aug;64(2):439-55. doi: 10.1002/hep.28541.



Structural basis for selective recognition of acyl chains by the membrane-associated acyltransferase PatA.

Albesa-Jové D, Svetlíková Z, Tersa M, Sancho-Vaello E, Carreras-González A, Bonnet P, Arrasate P, Eguskiza A, Angala SK, Cifuentes JO, Korduláková J, Jackson M, Mikušová K, Guerin ME.

Nat Commun. 2016 Mar 11;7:10906. doi: 10.1038/ncomms10906.



Liver receptor homolog 1 and transmethylation fluxes in nonalcoholic steatohepatitis


Mato JM, Lu SC.

Hepatology. 2016 Jan;63(1):17-9. doi: 10.1002/hep.28146



Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis

Zubiete-Franco I, García-Rodríguez JL, Martínez-Uña M, Martínez-Lopez N, Woodhoo A, Juan VG, Beraza N, Lage-Medina S, Andrade F, Fernandez ML, Aldámiz-Echevarría L, Fernández-Ramos D, Falcon-Perez JM, Lopitz-Otsoa F, Fernandez-Tussy P, Barbier-Torres L, Luka Z, Wagner C, García-Monzón C, Lu SC, Aspichueta P, Mato JM, Martínez-Chantar ML, Varela-Rey M.



Stratification and therapeutic potential of PML in metastatic breast cancer

Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, García S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C, Barrio R, Serra V, Vivanco Md, Matheu A, Gomis RR, Carracedo A.

Nat Commun. 2016 Aug 24;7:12595. doi:

Scientific Output Editorial Activity



Jesús Jiménez Barbero
Advisory Board



Jesús Jiménez Barbero
Editorial Board



Juán Anguita
Editorial Board



Edurne Berra
Editorial Board
Executive Editor



Jesús Jiménez Barbero
Editorial Board



Jesús Jiménez Barbero
Editorial Board



Jesús Jiménez Barbero
Editorial Advisory Board



Jesús Jiménez Barbero
Editorial Board



Jesús Jiménez Barbero
Editorial Board



Juan M. Falcón-Pérez
Editorial Board



Microbial Immunology

Juán Anguita
Review Editor

Endocrinology

Rosa Barrio
Review Editor



Oscar Millet
Associate Editor



María de Mar Vivanco
Editorial Board



Arkaitz Carracedo
Autophagy and Cell Death Section
Advisory Board



Rosa Barrio
Editorial Board



SCIENTIFIC REPORTS

Rosa Barrio
Editorial Board



CIC bioGUNE researchers publish again more than 100 publications. They include 20 publications with Impact Factor above 10. The average IF in 2016 reaches 6.5.

Competitive funding in CIC bioGUNE reaches 58% of total funding.

A new 600 MHz Bruker IVDr NMR instrument exclusively dedicated to metabolomics studies is installed at CIC bioGUNE.


A new research group (Structural Glycobiology) joins CIC bioGUNE.

CIC bioGUNE researchers obtain three new International projects in 2016.

This instrument will be essential for the development of a new Project on metabolic health of the Basque Country populations.

Atlas Molecular Pharma, a spin-off company from CIC bioGUNE, consolidates its Seed II Phase.

CIC bioGUNE joins the RIS3 Specialization Strategy at Euskadi in the area of Health.





Lectures

11th anniversary-lecture
Prof. Avelino Corma

Anniversary Lecture
January 29, 2016
12.00 H, CIC bioGUNE
(Atrio 800)

Prof. Avelino Corma
Instituto de Tecnología Química, Valencia

From basic knowledge to industrial applications

Avelino Corma (Moncofar, Castellón, Spain 1951) is Professor at the Institute of Chemical Technology (ITQ-CSIC-Polytechnical University of Valencia). He has worked on fundamental aspects of acid-base and redox catalysis with the aim of understanding the nature of the active sites and reaction mechanisms.

He is an internationally recognized expert in solid acid and bifunctional catalysts for oil refining, petrochemistry and chemical process, especially in the synthesis and application of zeolite catalysts. He has published more than 600 research papers, and is inventor of more than 100 patents. Over 12 of these patents have been industrially applied.

Among many other honors and distinctions, he has received the Prince of Asturias Award for Technical & Scientific Research (2014), Grande Médaille de l'Académie des sciences (France), (2011), the Scientific Merit of Generalitat Valenciana (2011), the Royal Society of Chemistry Centenary Prize (2010), the A. V. Humboldt - J. C. Mutis Research Award (2009), the Gabor A. Somogyi Award for Creative Research in Catalysis (2008), the National Award on Science and Technology of Mexico (2008), the Paul Sabatier of the French Society of Chemistry (2008), the Gold Medal of the Royal Society of Chemistry of Spain (2005), the Order of Merit Civil of Spain (2002), the F. Gault European Award on "Catalysis" (2001), the King Jaime I Award on "New Technologies" (Spain) (2000), the Iberdrola Science and Technology (Spain) (1998), the F. Ciappetta award of the North American Catalysis Society (1998), the National Award "Leonardo Torres Quevedo" (Spain) (1995),.....

Professor Corma has also been conferred with over 12 Honoris Causa recognitions, including Universidad de Cantabria (2016), Bucharest (2014), Delft University of Technology (2013), Ottawa (2012), Alicante (2010), Bochum (2010), Valencia (2009), Jaime I (2008), Technische Universität München (2008), UNED (2008), Utrecht University (2008).

He is a foreign Member of the Royal Society (UK), the National Academy of Engineering (USA), the President's International Advisory Council of King Abdullah University of Science KAUST, the Royal Academy of Exact, Physics and Natural Sciences of Spain, among many others.

He is also member of the SAB of CIC bioGUNE.

Synthetic Biology: Fundaments
and Current Developments
Prof. Andrew Hessel

CIC bioGUNE
Andrew Hessel
Autodesk Research,
San Francisco, CA, USA

**Synthetic Biology:
Fundaments and Current Developments**

Autodesk Distinguished Researcher Andrew Hessel is a catalyst in biological technologies, helping industry, academics, and authorities better understand the changes happening in life science. He is also the co-founder of the Pink Army Cooperative, the world's first cooperative biotechnology company, which is aiming to make open source viral therapies for cancer. He is a fellow at the University of Ottawa, Institute for Science, Society, and Policy, and the former co-chair of bioinformatics and biotechnology at Singularity University.

**Friday
June 10
CIC bioGUNE
Atrio 800
11.00H**

11:00H Lecture
12:00H Open Discussion

Organized by: **ih MONDRAGON Health** **CIC bioGUNE** **BASQUE BIOCLUSTER**

Christmas Lecture
Prof. Maurizio Prato

**December
15, 2016
12.00h**

**Christmas Lecture
Prof. Maurizio Prato**

**Nanomedicine Chemistry and Nanotechnology:
Synergies for a Better World**

Nanometer-scale structures represent a novel and intriguing field, where scientists and engineers manipulate materials at the atomic and molecular level to produce innovative materials for making composites and for electronic, sensing, and biomedical applications. Carbon nanomaterials, such as carbon nanotubes and graphene, constitute a relatively young class of materials exhibiting exceptional mechanical and electronic properties, and are also promising candidates for gas storage and drug delivery.

Processing of these novel building blocks is severely limited by a number of inherent problems: purification from a variety of impurities, difficult manipulation and low solubility in standard solvents are only some of these problems. For these reasons, several strategies have been devised to make carbon nanostructures "easier" materials. In particular, chemistry plays a fundamental role, since it leads to functionalized carbon nanostructures, which are much more easily processible and offers the possibility of introducing the desired functions, useful for practical applications.

During this talk, we will discuss how carbon nanotubes are ideal substrates for neuronal growth. Not only nanotubes are compatible with neurons, but especially they play a very interesting role in interneuron communication, opening possibilities towards applications in spinal cord repair therapy.

In addition, in combination with catalysts of different nature, carbon nanostructures can serve for many scopes. Experiments aimed at the production of molecular hydrogen, ideal for clean energy generation, will be described.

CIC bioGUNE **Parque Tecnológico de Bizkaia, Edif. 101 A Auditorium** **CIC bioGUNE**

Conferences

**INTERNATIONAL SOCIETY FOR
EXTRACELLULAR VESICLES**

Annual Meeting - ISEV2016
Rotterdam, The Netherlands

Co-organized by Juan M Falcón Pérez
4-7 May 2016

**EMBO
Conference**

**Translational research
in cancer cell metabolism**

4 - 6 October 2016 | Bilbao, Spain

Organized by Arkaitz Carracedo
4-6 Oct 2016

3rd International Symposium

Therapeutic applications of extracellular vesicles

29 - 30 September 2016
San Sebastián, Spain

Register now! Early bird deadline: 15 Jul 2016

GEIVEX

Co-organized by Juan M Falcón Pérez
29-30 Sept 2016

PROTEOSTASIS and its Biological Implications

2nd to 5th of November 2016
Leuven, Belgium

PROTEOSTASIS **cost**
EUROPEAN COOPERATION
IN SCIENCE AND TECHNOLOGY

Co-organized by Rosa Barrio
2-5 Nov 2016

Dissemination and Outreach 2016



Workshop



Joint Meeting
CIC biomaGUNE- CIC bioGUNE:
January 27, 2016



Joint Meeting
UPV/EHU (Biofisika)- CIC bioGUNE:
June 30, 2016



Rediex Workshop on exosome imaging
by REDiEX at @CNIO_cancer
Co-organized by Juan M Falcón Pérez
July 26-28, 2016

Some Activities



11th anniversary-lecture
Avelino Corma, Premio Príncipe de Asturias 2014



New MNR Equipment



5th anniversary



2º Encuentro Industrias Bio-Salud
Aquitania / Euskadi






Biospain (28-30 September) & Meeting
Biobasque - USA Delegation Biospain 2016.
September at CIC bioGUNE



CIC bioGUNE has joined the Agreement on
Openness on Animal Research promoted by the
Federation of Scientific Societies in Spain (COSCE)



We have also participated in...



Dissemination and Outreach 2016

Press clippings

La investigación vasca se une para arrojar luz sobre los enigmas de la fibromialgia

Profesionales de distintos ámbitos de la salud se unen para investigar sobre la fibromialgia, una enfermedad que afecta a millones de personas.



El estudio, liderado por el Dr. Juan Carlos Fernández-Cervera, se centra en comprender mejor los mecanismos de esta enfermedad y cómo afecta a la vida diaria de los pacientes.

Investigadores vascos descubren una llave maestra para frenar el avance del alzhéimer

Un laboratorio de Euzkadi ha conseguido identificar una proteína que actúa como una llave maestra para frenar el avance del alzhéimer.



El descubrimiento, liderado por el Dr. Juan Carlos Fernández-Cervera, podría abrir nuevas vías para el desarrollo de fármacos que frenen la progresión de esta enfermedad neurodegenerativa.

Bizkaia se enfunda la rosa para correr contra el cáncer de mamá

Un estudio de investigación en Bizkaia se enfunda la rosa para correr contra el cáncer de mamá. La tercera carrera popular y solidaria organizada por Aizami será el próximo 16 de octubre.



El evento, que se celebrará en el estadio de Anoeta, cuenta con el apoyo de la comunidad científica y empresarial de Bizkaia para apoyar la investigación en oncología.

Un estudio de CIC bioGUNE avanza en la lucha contra el cáncer de hígado y colon

Un estudio de investigación en colaboración con la Universidad de Liverpool, CIC bioGUNE ha abierto nuevas vías para el desarrollo de medicamentos que pueden ser la base de nuevos fármacos para combatir el cáncer de hígado y de colon.



Los investigadores están trabajando en el laboratorio de CIC bioGUNE para comprender mejor los mecanismos de estos tipos de cáncer y desarrollar terapias más efectivas.

Identifican una proteína que regula la respuesta de las células a la gripe

Investigadores del centro vasco CIC bioGUNE han identificado una proteína de las células inmunes de las vías respiratorias que permite regular su respuesta frente a agentes infecciosos como el resaca de la gripe.



Este descubrimiento, liderado por el Dr. Juan Carlos Fernández-Cervera, podría ayudar a comprender mejor cómo el sistema inmune responde a las infecciones y desarrollar vacunas más eficaces.

ESTRATEGIA [empresarial]

Aggregación | Competitividad | Desarrollo Sostenible | Editorial y la Forma | Actus | Ed | Inversión | Share-Tor | Ma |

CIC bioGUNE acoge una conferencia de Andrew Hessel, referente mundial en biología sintética

Es investigador de Autodesk Research San Francisco y co-fundador de Pink Army Cooperative, la primera cooperativa biotecnológica del mundo.



El sector de las biociencias en la salud, un gran potencial para Euskadi

Alfabeto interactivo en contenidos, con un flujo de 100 millones de euros al año.



Este sector tiene un gran potencial para el desarrollo económico de Euzkadi, especialmente en áreas como la medicina personalizada y la biología sintética.

Terapias a medida

LA MEDICINA



Los avances en biotecnología permiten desarrollar terapias personalizadas para cada paciente, mejorando los resultados de los tratamientos.

ESTRATEGIA [empresarial]

Aggregación | Competitividad | Desarrollo Sostenible | Editorial y la Forma | Actus | Ed | Inversión | Share-Tor | Ma |

Expertos internacionales se reúnen en Bilbao para discutir sobre cáncer

CIC bioGUNE organiza "Translational research in cancer cell metabolism", un congreso sobre metabolismo y cáncer.



CIC bioGUNE avanza en la cura del cáncer de mama más agresivo

Investigadores de Zamudio identifican una proteína vinculada a tumores triple negativo.



Este descubrimiento podría abrir nuevas vías para el desarrollo de terapias dirigidas contra este tipo de cáncer, que es uno de los más agresivos.

inno-tech

CIC bioGUNE inaugura un espectrómetro de Resonancia Magnética Nuclear

El innovador equipamiento se utilizará para el estudio de enfermedades metabólicas.



María del Mar Vivanco: "Quizá sea posible convertir el cáncer de mama en una enfermedad crónica"

María del Mar Vivanco lleva muchos años investigando sobre el cáncer de mama. Actualmente dirige un equipo en el centro CIC bioGUNE de Zamudio.



El descubrimiento de la proteína de la familia de los receptores de tirosina quinasa (RTK) podría ser una clave para comprender mejor los mecanismos de este tipo de cáncer y desarrollar terapias más efectivas.

CIC bioGUNE abre una línea para descubrir fármacos contra enfermedades raras

Junto a otras compañías, crea la empresa Atlas Molecular Pharma para este fin.



Este nuevo enfoque de investigación busca desarrollar terapias innovadoras para enfermedades raras, mejorando la calidad de vida de los pacientes.

Identifican un mecanismo que provoca metástasis en el cáncer de próstata

El equipo de investigadores vascos abre la puerta a nuevas terapias.



Este descubrimiento, liderado por el Dr. Juan Carlos Fernández-Cervera, podría ayudar a comprender mejor cómo se propagan las células cancerosas y desarrollar terapias para prevenir o tratar las metástasis.

La Academia de Ciencias Médicas de Bilbao nombra a Oscar Millet presidente de su sección de Investigación

La centenario institución interrelaciona la salud con la sociedad.



Este nombramiento reconoce el compromiso de Oscar Millet con la investigación científica y su contribución al avance de la medicina y la salud pública.